What is Nurix Therapeutics, Inc.'s D&A?

Nurix Therapeutics, Inc. (NRIX) reported D&A of $2.2M in Q4 2025.

How has Nurix Therapeutics, Inc.'s D&A changed year-over-year?

Nurix Therapeutics, Inc.'s D&A decreased by 6.6% year-over-year, from $2.35M to $2.2M.

What is the long-term trend for Nurix Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s D&A has grown at a 34.1% compound annual growth rate (CAGR), from $2.7M to $8.74M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Nurix Therapeutics, Inc. NRIX D&A

D&A at other companies

Kymera TherapeuticsKYMR

$2.02M-1.3%

Monte Rosa Therapeutics, Inc.GLUE

$2.03M-0.9%

Stoke Therapeutics, Inc.STOK

$439K-8.0%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

Nuvation BioNUVB

$536K+72.9%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

Other financials

Income statement

See full

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Balance sheet

See full

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Cash flow

See full

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Valuation

See full

Market cap$1.95B+40.1%

Enterprise value$1.94B+45.1%

P/S27.2×+2.5×

Profitability

See full

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Returns & leverage

See full

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s D&A?: Nurix Therapeutics, Inc. (NRIX) reported D&A of $2.2M in Q4 2025.
How has Nurix Therapeutics, Inc.'s D&A changed year-over-year?: Nurix Therapeutics, Inc.'s D&A decreased by 6.6% year-over-year, from $2.35M to $2.2M.
What is the long-term trend for Nurix Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s D&A has grown at a 34.1% compound annual growth rate (CAGR), from $2.7M to $8.74M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.